These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11993454)

  • 21. [Lung cancer].
    Komagata H; Yoneda S
    Gan To Kagaku Ryoho; 2004 Oct; 31(10):1609-13. PubMed ID: 15508459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating biomarkers for lung cancer.
    Buccheri G
    Ann Ital Chir; 1999; 70(6):831-8. PubMed ID: 10804657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum cytokine and chemokine profiles in neonates with meconium aspiration syndrome.
    Okazaki K; Kondo M; Kato M; Kakinuma R; Nishida A; Noda M; Taniguchi K; Kimura H
    Pediatrics; 2008 Apr; 121(4):e748-53. PubMed ID: 18346989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The role of serum markers in diagnosis and treatment monitoring in patients with lung cancer].
    Jassem E; Jassem J
    Przegl Lek; 1995; 52(8):392-4. PubMed ID: 8525011
    [No Abstract]   [Full Text] [Related]  

  • 25. Combination of markers may prove useful in screening for ovarian CA.
    Oncology (Williston Park); 1994 Jun; 8(6):79-80. PubMed ID: 8074986
    [No Abstract]   [Full Text] [Related]  

  • 26. [The value of serum tumor marker in the diagnosis of lung cancer].
    Shi GL; Hu XL; Yue SD; Song CX
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):299-301. PubMed ID: 15996327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
    Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
    Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Laboratory markers of melanoma progression].
    Bánfalvi T; Edesné MB; Gergye M; Udvarhelyi N; Orosz Z; Gilde K; Kremmer T; Ottó S; Tímár J
    Magy Onkol; 2003; 47(1):89-104. PubMed ID: 12704461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Granulocyte colony stimulating factor-producing collision tumor of the gastric cardia.
    Komatsu D; Sakurai M; Nakafuji H; Koide N; Morishita H; Nakamura T
    J Gastroenterol; 2003; 38(10):1013-5. PubMed ID: 14614613
    [No Abstract]   [Full Text] [Related]  

  • 30. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
    Gadducci A; Tana R; Cosio S; Genazzani AR
    Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in serum cytokine concentrations during the menopausal transition.
    Yasui T; Maegawa M; Tomita J; Miyatani Y; Yamada M; Uemura H; Matsuzaki T; Kuwahara A; Kamada M; Tsuchiya N; Yuzurihara M; Takeda S; Irahara M
    Maturitas; 2007 Apr; 56(4):396-403. PubMed ID: 17164077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?
    Bremnes RM; Sirera R; Camps C
    Lung Cancer; 2005 Jul; 49(1):1-12. PubMed ID: 15949585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
    Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
    Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic markers for stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N
    Lung Cancer; 2008 Feb; 59(2):274-5. PubMed ID: 18055061
    [No Abstract]   [Full Text] [Related]  

  • 35. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early detection of lung cancer using serum RNA or DNA markers: ready for "prime time" or for validation?
    Bunn PJ
    J Clin Oncol; 2003 Nov; 21(21):3891-3. PubMed ID: 14507944
    [No Abstract]   [Full Text] [Related]  

  • 37. [The plasma levels and diagnostic utility of granulocyte colony stimulating factor (G-CSF) and macrophage - colony stimulating factor (M-CSF) in ovarian cancer patients].
    ławicki S; Czygier M; Gacuta-Szumarska E; Knapp P; Szmitkowski M
    Pol Merkur Lekarski; 2006 Nov; 21(125):465-8. PubMed ID: 17345841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
    Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
    Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYFRA 21-1 in non-small cell lung cancer--standardisation and application during diagnosis.
    Pavićević R; Bubanović G; Franjević A; Stancić-Rokotov D; Samarzija M
    Coll Antropol; 2008 Jun; 32(2):485-98. PubMed ID: 18756899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum levels of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in treated patients with chronic myelogenous leukemia in chronic phase.
    Balleari E; Bason C; Visani G; Gobbi M; Ottaviani E; Ghio R
    Haematologica; 1994; 79(1):7-12. PubMed ID: 15378942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.